Raphael Pharmaceutical (RAPH) Enterprise Value (2023 - 2026)

Raphael Pharmaceutical has disclosed Enterprise Value across 4 years of filings, most recently posting $28.2 million for Q2 2026.

• In Q2 2026, Enterprise Value rose 92.15% year-over-year to $28.2 million; the TTM figure through Jun 2026 stood at $28.2 million (up 92.15% YoY), while the FY2025 annual figure was $28.2 million, up 482.28% from the prior year.
• Enterprise Value came in at $28.2 million for Q2 2026 at Raphael Pharmaceutical, roughly flat from $28.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $30.8 million in Q3 2024 to a low of $4.8 million in Q4 2024.
• Average Enterprise Value over 4 years is $20.0 million, with a median of $18.4 million recorded in 2024.
• The largest YoY upside for Enterprise Value was 482.28% in 2025 against a maximum downside of 74.54% in 2025.
• Over 4 years, Enterprise Value stood at $18.3 million in 2023, then tumbled by 73.49% to $4.8 million in 2024, then surged by 482.28% to $28.2 million in 2025, then increased by 0.16% to $28.2 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $28.2 million in Q2 2026, $28.2 million in Q4 2025, and $7.8 million in Q3 2025.